Changes in Gastrointestinal Microbiota Using VSL#3 in Patients With IBS-D
Recruitment status was: Not yet recruiting
To compare changes in gut microbiota of IBS patients and healthy controls using next generation sequencing method like Illumina sequencing based on 16S rDNA profiling.
The major objectives of the study are:
To characterize type of bacterial species and compare diversity of the host's gut microbiota in 20 Irritable bowel syndrome (IBS) patients with 16 healthy controls (HCs) using high through put culture-independent method like Illumina sequencing.
To study modulation of gut microbiota profile after treatment with probiotics (VSL #3) for 8 weeks.
To study the improvement of symptoms after modulation of gut microbiota with probiotics (VSL #3) for more than 8 weeks.
|Study Design:||Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Spectrum of Gastrointestinal Microbiota in Patients With IBS-D Before and After Treatment With VSL#3.|
- Improvement of symptoms after modulation of gut microbiota with probiotic, VSL#3 [ Time Frame: 8 wks ] [ Designated as safety issue: No ]To study modulation of gut microbiota profile after treatment with probiotics (VSL #3) for 8 weeks.
- Comparison of GI microbiota before and after treatment [ Time Frame: 8 wks ] [ Designated as safety issue: No ]To characterize type of bacterial species and compare diversity of the host's gut microbiota in 20 Irritable bowel syndrome (IBS) patients with 16 healthy controls (HCs) using high through put culture-independent method like Illumina sequencing.
|Study Start Date:||August 2012|
|Estimated Study Completion Date:||December 2012|
|Estimated Primary Completion Date:||December 2012 (Final data collection date for primary outcome measure)|
Patients with IBS-D as per ROME III
Dosage Form: Capsules (Details as given below); Dose and duration of treatment: 1 capsule b.i.d for 8 weeks; Each capsule contains 112.5 Billion CFU of the following 8 strains of bacteria, 4 lactobacilli strains (L. acidophilus, L. plantarum, L. paracasei, L. delbrueckii subsp bulgaricus), 3 bifidobacteria strains (B. breve, B. infantis, B. longum) and 1 strain of S. thermophilus).
Other Name: probiotic
No Intervention: Healthy Controls
The role of the commensal flora in many disease states, including irritable bowel syndrome, inflammatory bowel disease, and even obesity, is now accepted and will undoubtedly lead to new therapeutic strategies. The recently NIH-initiated Human Microbiome Project will allow better understanding of the role of this complex intestinal community in human health and disease. On the clinical side, we are exploring the more common pathogenic bacterial strains in Irritable bowel syndrome patients and use of probiotics in this functional gastrointestinal disease. We are taking support from Genotypic institute, Bangalore for Illumina sequencing facility.
Asian Institute of Gastroenterology, the parent institution, is a 200 bed tertiary care referral hospital providing services to patients with GI diseases, with a daily attendance of 400 out-patients and 200 in-patients. The long term goals of the investigators, involving basic researchers and clinicians, include development of technological resources and applications of biotechnology for use in clinical trials to improve survival rates of patients with GI diseases. The major volume of the outpatient cases comprise of patients with irritable bowel syndrome. Altered GI microbiota may contribute to IBS symptoms and studying dysbiosis in gut microbiota is an important to develop therapy for IBS.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01638208
|Asian Institute of Gstroenterology|
|Hyderabad, Andhra Pradesh, India, 500082|
|Principal Investigator:||Dr. Nitesh Pratap, DM||Asian Institute of Gastroenterology|
|Study Director:||Dr. Nageshwar Reddy, DM||Asian Institute of Gastroenterology|